northwest activity center vaccine schedule

Vaxelis ® can be used for catch-up vaccination in children less than age 5 years. Previously unvaccinated children age 60 months or older who are not considered high risk: Do not require catch-up vaccinationįor other catch-up guidance, see Table 2.Unvaccinated at age 15–59 months: Administer 1 dose.1 dose administered at age 15 months or older: No further doses needed.2 doses of PedvaxHIB ® before age 12 months: Administer dose 3 (final dose) at age 12–59 months and at least 8 weeks after dose 2.Dose 1 before age 12 months and dose 2 before age 15 months: Administer dose 3 (final dose) at least 8 weeks after dose 2.Dose 1 at age 12– 14 months: Administer dose 2 (final dose) at least 8 weeks after dose 1.Dose 1 at age 7– 11 months: Administer dose 2 at least 4 weeks later and dose 3 (final dose) at age 12–15 months or 8 weeks after dose 2 (whichever is later).For more information on Emergency Use Authorization (EUA) indications for COVID-19 vaccines, see. Current COVID-19 schedule and dosage formulation available at. See For Janssen COVID-19 Vaccine recipients see COVID-19 schedule at Note: Administer an age-appropriate vaccine product for each dose. Pre-exposure prophylaxis (monoclonal antibodies) may be considered to complement COVID-19 vaccination.Age 12–18 years: 3-dose series at 0, 4, 8 weeks (Moderna) or 2-dose series at 0, 3 weeks (Novavax) or 3-dose series at 0, 3, 7 weeks (Pfizer-BioNTech).Age 5–11 years: 3-dose series at 0, 4, 8 weeks (Moderna) or 3-dose series at 0, 3, 7 weeks (Pfizer-BioNTech).Age 6 months–4 years: 3-dose series at 0, 4, 8 weeks (Moderna) or 3-dose series at 0, 3, 11 weeks (Pfizer-BioNTech).Persons who are moderately or severely immunocompromised COVID-19 vaccines that are authorized or approved by the FDA are covered by the Countermeasures Injury Compensation Program (CICP). All vaccines included in the child and adolescent vaccine schedule are covered by VICP except for dengue, PPSV23 and COVID-19 vaccines. The National Vaccine Injury Compensation Program (VICP) is a no-fault alternative to the traditional legal system for resolving vaccine injury claims.For information about vaccination in the setting of a vaccine-preventable disease outbreak, contact your state or local health department.Itasca, IL: American Academy of Pediatrics 2021:72–86).

Red Book: 2021–2024 Report of the Committee on Infectious Diseases. For vaccination of persons with immunodeficiencies, see Table 8-1, Vaccination of persons with primary and secondary immunodeficiencies, in General Best Practice Guidelines for Immunization, Immunization in Special Clinical Circumstances (In: Kimberlin DW, Barnett ED, Lynfield Ruth, Sawyer MH, eds.Information on travel vaccination requirements and recommendations is available at.For further details, see Table 3-2, Recommended and minimum ages and intervals between vaccine doses, in General Best Practice Guidelines for Immunization. The repeat dose should be spaced after the invalid dose by the recommended minimum interval. Doses of any vaccine administered ≥5 days earlier than the minimum age or minimum interval should not be counted as valid and should be repeated as age-appropriate. Vaccine doses administered ≤4 days before the minimum age or interval are considered valid.Within a number range (e.g., 12–18), a dash (–) should be read as “through.”.Intervals of ≥4 months are determined by calendar months. For calculating intervals between doses, 4 weeks = 28 days.Consult relevant ACIP statements for detailed recommendations.Notesįor vaccination recommendations for persons ages 19 years or older, see the Recommended Adult Immunization Schedule, 2023. The use of trade names is for identification purposes only and does not imply endorsement by the ACIP or CDC. When a vaccine is not administered at the recommended age, administer at a subsequent visit. Do not restart or add doses to vaccine series for extended intervals between doses. (MenACWY-D: ≥9 mos, MenACWY-CRM: ≥2 mos, MenACWY-TT: ≥2years)Īdminister recommended vaccines if immunization history is incomplete or unknown. Tetanus, diphtheria, & acellular pertussis (RV) RV1 (2-dose series) RV5 (3-dose series)ĭiphtheria, tetanus, & acellular pertussis

Northwest activity center vaccine schedule